DNMT3A and acute myeloid leukemia: While the above observations suggest a role for the PI3K pathway in loss of Dnmt3a–induced hematopoietic abnormalities, we next examined whether human AML cells carrying a DNMT3A mutation respond to PI3K α/β inhibitor treatment in a manner similar to murine mutant cells.